{"filing":{"accession_number":"0001193125-26-345874","cik":"0001683553","ticker":"SPRB","company_name":"SPRUCE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"sprb-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1683553/000119312526345874/sprb-20260812.htm"},"events":[{"id":27087,"run_id":24659,"accession_number":"0001193125-26-345874","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Spruce Biosciences' financial results for Q2 2026 and the first six months of 2026, including cash position ($96.3M), R\u0026D expenses ($12.2M for Q2), G\u0026A expenses ($4.3M for Q2), and net loss ($16.2M for Q2, or $(6.68) per share). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial statements (condensed balance sheet and statements of operations) and material corporate updates regarding TA-ERT development milestones and leadership appointments.","company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28466,"accession_number":"0001193125-26-345874","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Spruce Biosciences' financial results for Q2 2026 and the first six months of 2026, including cash position ($96.3M), R\u0026D expenses ($12.2M for Q2), G\u0026A expenses ($4.3M for Q2), and net loss ($16.2M for Q2, or $(6.68) per share). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial statements (condensed balance sheet and statements of operations) and material corporate updates regarding TA-ERT development milestones and leadership appointments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T13:06:16.655250+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28466,"accession_number":"0001193125-26-345874","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Spruce Biosciences' financial results for Q2 2026 and the first six months of 2026, including cash position ($96.3M), R\u0026D expenses ($12.2M for Q2), G\u0026A expenses ($4.3M for Q2), and net loss ($16.2M for Q2, or $(6.68) per share). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial statements (condensed balance sheet and statements of operations) and material corporate updates regarding TA-ERT development milestones and leadership appointments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T13:06:16.655250+00:00","company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","filing_date":"2026-08-12"}]}